Abstract
Anemia is found in about 60% of patients with disseminated neoplasti disease (Ultmann and Golomb 1983). The definition of chronic anemia of cancer as a specific subset of anemia is based on the exclusion of iron depletion, vitamin deficiency, hemolysis, and renal failure as underlying causes (Cartwright 1971) and on the evidence of low or normal serum iron and transferrin levels combined with normal or increased ferritin concentration. So far there is no agreement on whether anemia due to myelophthisis and cytotoxic treatment accompanied by impairment of iron metabolism should be considered as chronic tumor associated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cartwright GE (1971) The anemia of chronic disorders. Br J Haematol 21: 147–152
Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffmann R (1983) Mechanisms of abnormal erythropoiesis in malignancy. Cancer 51: 1101–1106
Douglas SW, Adamson JW (1975) The anemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 45: 55–65
Fisher JW, Roh BL (1964) Influence of alkylating agents on kidney erythropoietin production. Cancer 24: 983–988
Gascon P. Zoumbos NC, Young NS (1984) Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med 100: 173–177
Haurani FI, Young K, Tocantins LM (1963) Reutilization of iron complicating malignant neoplasmas. Blood 22: 73–81
Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD (1989) Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74: 130–138
Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Eng J Med 322: 1693–1699
Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spival JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Eng J Med 322: 1689–1692
Ost er W, Herrmann F, Cicco A, Gamm H, Zeile G, Brune T, Lindemann A, Schulz G, Mertelsmann R (1990a) Erythropoietin prevents chemotherapy-induced anemia: case report. Blut 60: 88–92
Oster W. Herrmann F, Gamm H, Zeile G, Lindemann A, Müller G, BruneT, Kraemer HP, Mertelsmann R (1990b) Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8: 956–962
Pecherstorfer M, Schmoranzer F, Vesely M, Fortelny A, Baumgartner G (1990) Erythropoietin in multiple myeloma. Dtsch Med Wochenschr 115: 1096–1099
Ultmann JE, Golomb HM (1983) Principles of neoplasia: approach to diagnosis and management. In: Petersdorf RG, Adams RD, Braunwald E, Isselbacher KJ, Martin JB, Wison JD (ed) Harrison’s principles of internal medicine, 10th edn. McGraw Hill, New York, p 784
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Pecherstorfer, M., Janisch, S., Zimmer-Roth, I. (1992). Erythropoietin in Neoplastic Diseases: Preliminary Results. In: Pagel, H., Weiss, C., Jelkmann, W. (eds) Pathophysiology and Pharmacology of Erythropoietin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77074-6_35
Download citation
DOI: https://doi.org/10.1007/978-3-642-77074-6_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77076-0
Online ISBN: 978-3-642-77074-6
eBook Packages: Springer Book Archive